Skip to main content
. 2024 Aug 23;8(20):5371–5381. doi: 10.1182/bloodadvances.2024013726

Figure 4.

Figure 4.

Comparison between TAFA-LEN and LEN as initial therapies for progression after CAR T-cell therapy. PFS (A) and OS (B) since the first treatment for progression after CAR T-cell therapy according to IPW using SW between TAFA-LEN and LEN (single agent).